Topical 2% Povidone-Iodine Gel in Verruca Vulgaris
Public ClinicalTrials.gov record NCT04253912. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris
Study identification
- NCT ID
- NCT04253912
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Veloce BioPharma LLC
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- VBP-245 Drug
- Placebo Gel (no Povidone-Iodine) Drug
Drug
Eligibility (public fields only)
- Age range
- 8 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2020
- Primary completion
- Jan 4, 2021
- Completion
- Mar 31, 2021
- Last update posted
- Mar 31, 2021
2020 – 2021
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Veloce BioPharma Clinical Trial Site | Hunt Valley | Maryland | 21030 | — |
| Veloce BioPharma Clinical Trial Site | Plymouth Meeting | Pennsylvania | 19462 | — |
| Veloce BioPharma Clinical Trial Site | Sugarloaf | Pennsylvania | 18429 | — |
| Veloce BioPharma Clinical Trial Site | Upper Saint Clair | Pennsylvania | 15241 | — |
| Veloce BioPharma Clinical Trial Site | Fort Mill | South Carolina | 29708 | — |
| Veloce BioPharma Clinical Trial Site | Arlington | Virginia | 22209 | — |
| Veloce BioPharma Clinical Trial Site | Lynchburg | Virginia | 24501 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04253912, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04253912 live on ClinicalTrials.gov.